The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Montelukast Bluefish 5 mg chewable tablets

Bluefish Pharmaceuticals ABPA1436/033/002

Main Information

Trade NameMontelukast Bluefish 5 mg chewable tablets
Active SubstancesMontelukast sodium
Dosage FormChewable tablet
Licence HolderBluefish Pharmaceuticals AB
Licence NumberPA1436/033/002

Group Information

ATC CodeR03DC03 montelukast


License statusAuthorised
Licence Issued10/09/2021
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0023-001-007
Interchangeable List DocumentPDF of Interchangeable List
« Back